For research use only. Not for therapeutic Use.
Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD)[1][2].
| Catalog Number | I041845 |
| CAS Number | 1788032-39-2 |
| Purity | ≥95% |
| Reference | [1]. Song C, et al. Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18. [2]. Imbimbo BP, et al. A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. Alzheimers Dement. 2022 May;18(5):1008-1037. |
